vTv Therapeutics appoints Elizabeth Keiley as EVP and General Counsel

vTv Therapeutics Inc.

Elizabeth Keiley appointed Executive Vice President and General Counsel, effective immediately.
Keiley brings legal experience from Entasis Therapeutics, Oxford Immunotec, and Zimmer.
She will support vTv's capital funding goals and upcoming Phase 3 trials for TTP399.
vTv is a clinical-stage biopharma focused on oral treatments for type 1 diabetes and cystic fibrosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.